GLP_1 RA Ultrasound Study

The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Glucagon Like Peptide-1 (GLP-1 Body Weight Delayed Gastric Emptying Diabetes Diabetes Mellitus Digestive System Diseases Endocrine System Diseases Gastrointestinal Diseases Gastroparesis Glucose Metabolism Disorders Metabolic Diseases Morbid Obesity Neurologic Manifestations Nutrition Disorders Nutritional and Metabolic Diseases Obesity Obesity, Morbid Overnutrition Overweight Paralysis Pathological Conditions, Signs and Symptoms Risk of Aspiration Signs and Symptoms Stomach Diseases

Age range

10 year–25 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Cincinnati Children's Hospital

Cincinnati, Ohio, 45299, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Body Mass Index over 35
Type 2 Diabetes
Currently taking GLP01 RA agonist (for GLP 1 group)
Not taking GLP-1 RA agonist (for control group)

Exclusion criteria

Diagnosis of gastroparesis
patient refusal to participate
Previous gastric bypass or any other gastric surgery
Currently on peritoneal dialysis
Abdominal pathology
Gastro-intestinal obstruction
Pregnancy

Treatment and study plan

Glucagon-Like Peptide-1 receptor agonists

Drug

GLP-1 RAs: Glucagon like peptide-1 receptor agonists, this includes patients who are on Liraglutide, Semaglutide, Dulaglutide and Tirzepatide.Tirzepatide which is a combined GLP-1 RA/glucose-dependent insulinotropic polypeptide (GIP) agonist is included as a part of GLP-1 RAs.

Point of Care Gastric Ultrasound

Diagnostic Test

A gastric ultrasound following a standard NPO period to determine gastric contents and risk of aspiration during surgery.

Other names: POGUS

Primary outcomes

Aspiration Risk determined by POGUS

Time frame: Two years

Difference between control group and GLP-1 group. Measured by Gastric contents during Point of Care Gastric Ultrasound.

Sponsors and collaborators

Lead sponsor

Children's Hospital Medical Center, Cincinnati

Other

Registry information

Official study title

Assessment of Gastric Contents in Patients Taking Glucagon-Like Peptide-1 Receptor Agonists: a Prospective Observational Cross-sectional Study

Important dates

Study start: 2024
Primary completion: 2026
Study completion: 2026
First posted: Sep 3, 2024
Registry last updated: Nov 7, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed